Dexcom has rounded up its celebrity spokespeople for World Diabetes Day, putting singer Nick Jonas at the center of a campaign intended to help people change their perception of what they can achieve.

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly ...

Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share. Read More on DXCM: DexCom NewsMORE Related Stocks Indices ...

In what makes Abbott Laboratories a serious competitor is the much lower price one has to pay for FreeStyle Libre - in comparison to Dexcom's G6 (or G7) and also in comparison to Medtronic's Guardian.

Amid the launch of its first over-the-counter wearable glucose tracker, Dexcom reported that its overall revenues in the U.S. declined year over year despite overall sales coming in slightly ...

DexCom reports quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue comes in at $994.2 million, which beat the analyst consensus ...

DexCom (DXCM) reported $994.2 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 2%. EPS of $0.45 for the same period compares to $0.50 a year ago.

DexCom (NASDAQ:DXCM) reported third-quarter earnings that surpassed analyst expectations, but the company's stock plummeted 16% as revenue growth slowed significantly. The continuous glucose ...

Shares of Dexcom (NASDAQ:DXCM) fell 16% in post-market trading Thursday after the company released its Q3 earnings report which showed only modest topline growth over last year’s quarter.

Oct 24 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for third-quarter revenue and profit on Thursday, helped by resilient demand for its continuous ...